K. MacDonald

发表

Evaluation of the feasibility of a school-based asthma management programme in Taiwan.

Yue-Cune Chang, S. Maa, Yu-ming Shen, 2010, Journal of clinical nursing.

Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study

L. V. Van Gaal, K. Denhaerynck, I. Abraham, 2019, Diabetes Therapy.

Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study)

K. Denhaerynck, I. Abraham, K. MacDonald, 2020, Clinical ophthalmology.

Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.

I. Abraham, A. Altyar, K. MacDonald, 2015, Clinical therapeutics.

Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.

M. Aapro, I. Abraham, K. MacDonald, 2014, Future oncology.

Biosimilars in 3D

I. Abraham, A. Altyar, K. MacDonald, 2013, Bioengineered.

Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer

I. Abraham, A. McBride, K. MacDonald, 2021, Journal of medical economics.

Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018

I. Abraham, B. Ortiz, K. MacDonald, 2019, Expert review of clinical immunology.

Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic re

I. Abraham, B. Ortiz, K. MacDonald, 2019 .

Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis

M. Aapro, I. Abraham, Abdullah A. Alhifany, 2019, Supportive Care in Cancer.

Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: Review and pooled analysis of observational studies.

Hee-Ju Kim, I. Abraham, A. McBride, 2017, Leukemia research.

Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.

M. André, K. van Eygen, W. Pluymers, 2014, Leukemia research.

Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients

K. Denhaerynck, I. Abraham, K. MacDonald, 2017, International journal of chronic diseases.

Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study).

L. V. Van Gaal, K. Denhaerynck, I. Abraham, 2016, Primary care diabetes.

Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study

G. London, C. Combe, D. Goldsmith, 2019, BMC Nephrology.

A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study

G. London, L. Gesualdo, C. Combe, 2013, Internal and Emergency Medicine.

Clinical safety of biosimilar recombinant human erythropoietins

I. Abraham, K. MacDonald, 2012, Expert opinion on drug safety.

Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer.

I. Abraham, A. McBride, K. MacDonald, 2021, Future oncology.

Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim

I. Abraham, A. McBride, K. MacDonald, 2020, Journal of medical economics.

Evidence for Cholesterol Hyperabsorbers and Hyperproducers Based on Comparative Low-Density Lipoprotein Reductions Achieved by Ezetimibe Versus Statins

K. MacDonald, J. Senaratne, M. Senaratne, 2012, Journal of cardiopulmonary rehabilitation and prevention.

No margin for non-adherence: Probabilistic kaplan-meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study).

S. De Geest, I. Abraham, K. MacDonald, 2021, Leukemia research.

Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study

G. London, C. Combe, N. Hoebel, 2017, Clinical nephrology.

Modelling of blood pressure and total cardiovascular risk outcomes after second-line valsartan therapy: the BSCORE study.

Yu-ming Shen, R. Lins, I. Abraham, 2011, Archives of cardiovascular diseases.

Promoting evidence-based management of anemia in cancer patients: background, development, and scientific validation of RESPOND, a web-based clinical guidance system based on the EORTC guidelines.

M. Aapro, I. Abraham, M. Muenzberg, 2008, Critical reviews in oncology/hematology.

Detectability and acceptability of continuous pulse signals for the MemoPatch® device, an electronic skin patch intended to deliver tactile medication reminder signals

I. Abraham, K. MacDonald, J. D. de Geest, 2015, Medical devices.

Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study.

S. De Geest, L. Dirix, C. Focan, 2011, Anticancer research.

The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.

Janzen, A. M. Møller, D. Debanne, 1996, The Canadian journal of cardiology.

Predicting blood pressure outcomes using single-item physician-administered measures: a retrospective pooled analysis of observational studies in Belgium.

K. Denhaerynck, I. Abraham, C. Hermans, 2015, The British journal of general practice : the journal of the Royal College of General Practitioners.

Impact of Cardiac Rehabilitation on the Ability of Elderly Cardiac Patients to Perform Common Household Tasks

P. Manns, W. Rodgers, K. MacDonald, 2011, Journal of cardiopulmonary rehabilitation and prevention.

Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

C. Bokemeyer, M. Boccadoro, M. Aapro, 2016, Supportive Care in Cancer.

The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines

C. Bokemeyer, M. Aapro, H. Ludwig, 2008, Supportive Care in Cancer.

Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim.

M. Aapro, P. Gascón, H. Ludwig, 2011, Critical reviews in oncology/hematology.

Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma.

I. Abraham, A. McBride, K. MacDonald, 2021, Leukemia research.

Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment

I. Abraham, A. McBride, K. MacDonald, 2021, Journal of medical economics.

Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: e

I. Abraham, A. McBride, K. MacDonald, 2021 .

Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv

I. Abraham, A. McBride, K. MacDonald, 2020, Journal of medical economics.

Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma

I. Abraham, A. McBride, K. MacDonald, 2020, Journal of medical economics.

Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.

C. Bokemeyer, M. Boccadoro, M. Aapro, 2019, Future oncology.

Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated “same-day” (< 24 h), “per-guidelines” (24–72 h), and “late” (> 72 h): findings from the MONITOR-GCSF study

C. Bokemeyer, M. Boccadoro, M. Aapro, 2018, Supportive Care in Cancer.

Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.

I. Abraham, A. McBride, K. MacDonald, 2017, Future oncology.

Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia

I. Abraham, A. McBride, K. MacDonald, 2017, Journal of medical economics.

Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study).

C. Bokemeyer, M. Boccadoro, M. Aapro, 2017, Journal of geriatric oncology.

Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study

C. Bokemeyer, M. Boccadoro, M. Aapro, 2017, Supportive Care in Cancer.

Clinical efficacy and safety of Zarzio ® (EP2006), a biosimilar recombinant human granulocyte colony-stimulating factor

I. Abraham, K. MacDonald, A. Bagalagel, 2014 .

Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors

I. Abraham, K. MacDonald, S. Tharmarajah, 2013, Expert opinion on drug safety.

Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments.

M. Boccadoro, M. Aapro, P. Gascón, 2011, Critical reviews in oncology/hematology.

Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study.

C. Bokemeyer, M. Aapro, T. Albrecht, 2009, European journal of cancer.

Assessment of Reproducibility of Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry for Bacterial and Yeast Identification

C. Ginocchio, C. Burnham, L. Westblade, 2015, Journal of Clinical Microbiology.

Safety of erythropoiesis-stimulating agents in patients with end-stage kidney disease: data are safer than extrapolations

I. Abraham, K. MacDonald, 2012, Expert opinion on drug safety.

"Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis.

I. Abraham, K. MacDonald, A. Alhossan, 2017, The journal of allergy and clinical immunology. In practice.

Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ‘real-world’ evidence

J. Bernstein, K. Denhaerynck, I. Abraham, 2018, Expert opinion on biological therapy.

Clinical efficacy and safety of XM01, a biosimilar recombinant human erythropoietin, in the management of anemia

I. Abraham, K. MacDonald, A. Bagalagel, 2013 .

Modeling of treatment response to erythropoiesis-stimulating agents in older (age≥70years) and younger (age<70years) patients with cancer and anemia: findings from the Anemia Cancer Treatment study.

C. Bokemeyer, M. Aapro, H. Ludwig, 2013, Journal of geriatric oncology.

Gender-stratified hierarchical modeling of patient and physician determinants of antihypertensive treatment outcomes: pooled analysis of seven prospective real-world studies with 17,044 patients

K. Denhaerynck, I. Abraham, K. MacDonald, 2021, Current medical research and opinion.

Intraclass correlation metrics for the accuracy of algorithmic definitions in a computerized decision support system for supportive cancer care

C. Bokemeyer, M. Aapro, J. Foubert, 2007, Supportive Care in Cancer.

Clinical Trials and Observations

L. Staudt, T. Greiner, D. Weisenburger, 2007 .

Meta-Analysis of Same-Day Pegfilgrastim Administration Stratified by Myelotoxic Febrile Neutropenia Risk and Tumor Type

I. Abraham, Jennifer R Martin, A. McBride, 2022, Journal of the advanced practitioner in oncology.

Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes

W. Pluymers, I. Abraham, M. Delforge, 2011, Annals of Hematology.

Remission Over 3 Years in Patients with Paget Disease of Bone Treated with a Single Intravenous Infusion of 5 mg Zoledronic Acid

P. Geusens, S. Boonen, J. Devogelaer, 2013, Calcified Tissue International.

Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy

I. Abraham, K. MacDonald, M. Chioda, 2021, Journal of medical economics.

‘Real-world’ effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis

I. Abraham, K. MacDonald, A. Alhossan, 2020, Expert review of clinical immunology.

Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of “Real-world” Evidence

J. Bernstein, K. Denhaerynck, I. Abraham, 2019, JAMA dermatology.

Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Adherent vs Nonadherent Hypertensive Patients: Pooled Analysis of 6 Studies With 14,646 Evaluable Patients

K. Denhaerynck, I. Abraham, C. Hermans, 2013, Journal of clinical hypertension.

Measuring the quality of nursing care to Alzheimer's patients.

D. Nadzam, K. MacDonald, I. Abraham, 2006, The Nursing clinics of North America.

Effectiveness of Amlodipine-Valsartan Single-Pill Combinations: Hierarchical Modeling of Blood Pressure and Total Cardiovascular Disease Risk Outcomes (the EXCELLENT Study)

Yu-ming Shen, R. Lins, I. Abraham, 2011, The Annals of pharmacotherapy.

Effectiveness of Valsartan for Treatment of Hypertension: Patient Profiling and Hierarchical Modeling of Determinants and Outcomes (the Preview Study)

K. Denhaerynck, I. Abraham, C. Hermans, 2009, The Annals of pharmacotherapy.

Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program

I. Abraham, C. Hermans, K. MacDonald, 2011, Vascular health and risk management.

Hierarchical linear and logistic modeling of outcomes of antihypertensive treatment in elderly patients: findings from the PREVIEW study.

I. Abraham, C. Hermans, P. Van der Niepen, 2010, Archives of gerontology and geriatrics.

Effects of Recombinant Human Type I Pancreatic Elastase on Human Atherosclerotic Arteries

B. Starcher, K. MacDonald, S. Burke, 2014, Journal of cardiovascular pharmacology.

Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study)

G. London, L. Gesualdo, C. Combe, 2015, International Urology and Nephrology.

Clinical efficacy and safety of Tevagrastim ® (XM02), a biosimilar recombinant human granulocyte colony-stimulating factor

I. Abraham, K. MacDonald, A. Mohammed, 2013 .

Clinical efficacy and safety of Tevagrastim ® (XM02), a biosimilar recombinant human granulocyte colony-stimulating factor

I. Abraham, K. MacDonald, A. Mohammed, 2013 .

Reducing waiting lists for laparoscopic cholecystectomy: An intensive approach to aid COVID-19 recovery

R. Clifford, K. Rajput, K. MacDonald, 2021, European Surgery.

Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study

J. Rakic, K. Denhaerynck, I. Abraham, 2013, Clinical ophthalmology.

“Later, lazier, and unluckier”: a heuristic profile of high vulnerability is an independent predictor of uncontrolled blood pressure (the PREVIEW study)

I. Abraham, C. Hermans, P. Van der Niepen, 2010, International journal of general medicine.

Promoting evidence-based management of anemia in cancer patients: concurrent and discriminant validity of RESPOND, a web-based clinical guidance system based on the EORTC guidelines for supportive care in cancer

Ivo Abraham, Pierre Soubeyran, Matti Aapro, 2010, Supportive Care in Cancer.

Should a Systematic Review Be Required in a Clinical Trial Report? Perhaps, But Not Yet.

I. Abraham, K. MacDonald, M. Calamia, 2023, JAMA network open.

Patient and caregiver outcomes after 6 ± 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease:the Belgian FExT study

T. Mets, I. Abraham, M. Vandewoude, 2007, Current medical research and opinion.

Subcutaneous Versus Intravenous Rituximab in Non-Hodgkin Lymphoma Treated with R-CHOP: Economic Modeling for the US

I. Abraham, A. McBride, K. MacDonald, 2018, Blood.

Reply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia

I. Abraham, A. McBride, K. MacDonald, 2018, Journal of medical economics.

Adherence to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia: Meta-Analyses of Prevalence Rates By Measurement Method

I. Abraham, K. MacDonald, A. Alhossan, 2016 .

Efficacy of Same-Day Vs. Next-Day Pegfilgrastim for the Prevention of Chemotherapy-Induced (Febrile) Neutropenia (CIN/FN): A Meta-Analysis

I. Abraham, Jennifer R Martin, A. McBride, 2015 .

Does synthetic pharmacotherapy still have a place in treating chronic spontaneous urticaria?

I. Abraham, K. MacDonald, M. Fazel, 2022, Expert opinion on pharmacotherapy.

Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study

K. Denhaerynck, I. Abraham, K. MacDonald, 2020, Clinical ophthalmology.

OPTH_A_242547 1473..1481

K. Denhaerynck, I. Abraham, K. MacDonald, 2020 .

Six-year outcomes in neovascular age-related macular degeneration with ranibizumab.

K. Denhaerynck, I. Abraham, J. Jacob, 2017, International journal of ophthalmology.

Remission Over 3 Years in Patients with Paget Disease of Bone Treated with a Single Intravenous Infusion of 5 mg Zoledronic Acid

P. Geusens, S. Boonen, J. Devogelaer, 2013, Calcified Tissue International.

Longitudinal observational studies to study the efficacy-effectiveness gap in drug therapy: application to mild and moderate dementia.

I. Abraham, K. MacDonald, S. Vancayzeele, 2006, The Nursing clinics of North America.

Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: initial evidence from the RESPOND study.

M. Aapro, T. Albrecht, I. Abraham, 2009, European journal of cancer.

Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.

Amit Goyal, I. Abraham, K. MacDonald, 2022, Journal of managed care & specialty pharmacy.

Acupressure Improves the Weaning Indices of Tidal Volumes and Rapid Shallow Breathing Index in Stable Coma Patients Receiving Mechanical Ventilation: Randomized Controlled Trial

Horng-Chyuan Lin, S. Maa, I. Abraham, 2013, Evidence-based complementary and alternative medicine : eCAM.

Exploring Discordance Between Patients and Clinicians-Understanding Perceived Disease Severity.

J. Barbieri, K. MacDonald, 2023, JAMA dermatology.

Clinical, Quality of Life, Patient Adherence, and Safety Outcomes of Short-Course (12 Weeks) Treatment with Cyclosporine in Patients with Severe Psoriasis (the Practice Study)

K. Denhaerynck, I. Abraham, C. Hermans, 2013, Annals of dermatology.

Quantity and Quality of Daily Physical Activity in Older Cardiac Patients.

K. MacDonald, R. Haennel, R. Lightfoot, 2015, Canadian journal of cardiovascular nursing = Journal canadien en soins infirmiers cardio-vasculaires.

Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients.

I. Abraham, A. McBride, K. MacDonald, 2021, Future oncology.

Prospective, randomized, fellow eye comparison of WaveLight® Allegretto Wave® Eye-Q versus VISX CustomVueTM STAR S4 IRTM in photorefractive keratectomy: analysis of visual outcomes and higher-order aberrations

J. Rakic, K. Denhaerynck, I. Abraham, 2011, Clinical Ophthalmology.

What does it take to provide cancer patients with comprehensive medication therapy management services for oral chemotherapy?

I. Abraham, A. McBride, K. MacDonald, 2016, Expert opinion on drug safety.

Meta-Analysis of Same-Day Pegfilgrastim Administration Stratified by Myelotoxic Febrile Neutropenia Risk and Tumor Type

I. Abraham, Jennifer R Martin, A. McBride, 2022, Journal of the advanced practitioner in oncology.

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

S. Geest, P. Martiat, G. Verhoef, 2009, Blood.

Why are patients with chronic myeloid leukaemia (non-)adherent?

I. Abraham, K. MacDonald, K. MacDonald, 2012, British Journal of Cancer.

Patient- and physician-level determinants of blood pressure response to treatment in normal weight and overweight patients (the PREVIEW study).

I. Abraham, C. Hermans, P. Van der Niepen, 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Effectiveness of a planned strategy using cardiac rehabilitation nurses for the management of dyslipidemia in patients with coronary artery disease.

K. MacDonald, M. Senaratne, J. Griffiths, 2001, American heart journal.

Antihypertensive effectiveness of aliskiren for the ‘real‐world’ management of hypertension: multilevel modelling of 180‐day blood pressure outcomes (the Belgian DRIVER Study)

I. Abraham, C. Hermans, K. MacDonald, 2011, International journal of clinical practice.

International Journal of General Medicine Dovepress Dovepress 163 R a P I D C O M M U N I C at I O N

C. Hermans, K. MacDonald, S. Vancayzeele, 2022 .

Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.

K. MacDonald, Marc Pondel, Ivo Abraham, 2024, Journal of medical economics.

Biosimilars in 3D

I. Abraham, A. Altyar, K. MacDonald, 2013, Bioengineered.

Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study.

C. Bokemeyer, M. Aapro, T. Albrecht, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Modelling of blood pressure outcomes in patients with and without established cardiovascular or renal disease following treatment with valsartan (the PREVIEW study).

I. Abraham, C. Hermans, K. MacDonald, 2013, Archives of cardiovascular diseases.

Modelling of blood pressure and total cardiovascular risk outcomes after second-line valsartan therapy: the BSCORE study.

Yu-ming Shen, R. Lins, I. Abraham, 2011, Archives of cardiovascular diseases.

Gender-specific, multi-level determinants of outcomes of antihypertensive treatment: a sub-analysis of the Belgian PREVIEW study

I. Abraham, C. Hermans, K. MacDonald, 2011, Journal of Human Hypertension.

Clinical safety of biosimilar recombinant human erythropoietins

I. Abraham, K. MacDonald, 2012, Expert opinion on drug safety.